CD79b expression in B cell chronic lymphocytic leukemia: its implication for minimal residual disease detection

Abstract

The surface expression of CD79b, using the monoclonal antibody (Mab) CB3-1, on B lymphocytes from normal individuals and patients with B cell chronic lymphocytic leukemia (CLL) has been analyzed using triple-staining cells for flow cytometry. In addition, the clinical significance of CD79b expression in CLL patients and its possible value for the evaluation of minimal residual disease (

Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation

“…We found that from all flow cytometric approaches tested, only the four-color immunophenotype CD19 þ CD5 þ CD43 þ CD20 low was 100% specific for CLL in comparison to ASO IgH RQ-PCR up to a maximum sensitivity of 2.2E-4. Surprisingly, in spite of the upregulation of CD5 on benign B cells after SCT (our unpublished data and demonstrated before 46,47 ), CD19 þ CD5 þ CD20 low remained a specific threecolor immunophenotype for CLL cells (2.2% false positive samples). Moreover, CD19 þ CD5 þ CD20 low proved to be slightly more sensitive than CD19 þ CD5 þ CD43 þ CD20 low and considerably more sensitive than CD19 þ CD43 þ CD20 low .…”

Surface antigen expression in chronic lymphocytic leukemia: clustering analysis, interrelationships and effects of chromosomal abnormalities

“…37 This was not observed at the protein level in the current work. The explanation may be that the extracellular epitope of CD79b is not necessarily expressed, 38 despite the presence of the pertinent mRNA species. 39 In conclusion, our results revealed a large group of CLL surface membrane antigens with a heterogeneous expression pattern.…”

Normal levels of peripheral CD19+CD5+ CLL‐like cells: Toward a defined threshold for CLL follow‐up—A GEIL‐GOELAMS study

“…Moreover, it imposes to know beforehand the type of light chain expressed at diagnosis on malignant cells for a given patient. Other antibodies such as CD20, CD79b, CD22, and CD43 have demonstrated their usefulness in the characterization of CLL cells and MRD evaluation and more recent fourcolor flow cytometry studies have reported an increased sensitivity of their detection down to the expected threshold of 10 À4 (23)(24)(25)(26)(27). These approaches are universal as they can be used for every patient and allow for a simple straightforward and recommended single-step labeling followed by lysis-no-wash on a small volume of whole blood of about 100 lL (28).…”